Review anchor
Cystic fibrosis transmembrane conductance regulator
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Cystic fibrosis transmembrane conductance regulator
CHEMBL4051
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cystic fibrosis transmembrane conductance regulator as ChEMBL target CHEMBL4051, mapped to UniProt P13569. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4051
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P13569
Cystic fibrosis transmembrane conductance regulator
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Cystic fibrosis transmembrane conductance regulator matters
Cystic fibrosis transmembrane conductance regulator is reviewed as Cystic fibrosis transmembrane conductance regulator (UniProt P13569); Cystic fibrosis transmembrane conductance regulator shows approved-linked disease relevance led by cystic fibrosis. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 1362 compounds, and 476 assays, with lead potency reaching pChEMBL 9.7.
Protein context
Cystic fibrosis transmembrane conductance regulator
Cystic fibrosis transmembrane conductance regulator Sequence length is 1480 aa.
Review this target as Cystic fibrosis transmembrane conductance regulator, mapped to UniProt P13569. Sequence length is 1480 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P13569
Protein
Disease context
cystic fibrosis
Cystic fibrosis transmembrane conductance regulator shows approved-linked disease relevance led by cystic fibrosis. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BAMOCAFTOR, DEUTIVACAFTOR, ELEXACAFTOR.
Start review with cystic fibrosis because it currently carries approved-linked support. Linked drugs include BAMOCAFTOR, DEUTIVACAFTOR, ELEXACAFTOR, GALICAFTOR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
11 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 1362 compounds, and 476 assays for this target. The dominant activity type is EC50. CHEMBL5863288 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL5863288 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 9.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Cystic fibrosis transmembrane conductance regulator matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P13569, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why cystic fibrosis is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1362
Total Compounds
476
Total Assays
5
Approved Drugs
IC50: 157.0, KI: 3.0, EC50: 1295.0, KD: 19.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5863288
|
9.7 | EC50 | — |
|
|
No preferred name
CHEMBL5178232
|
9.4 | EC50 | — |
|
|
No preferred name
CHEMBL5861582
|
9.4 | EC50 | — |
|
|
No preferred name
CHEMBL5802461
|
9.4 | EC50 | — |
|
|
No preferred name
CHEMBL5892004
|
9.4 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TEZACAFTOR
CHEMBL3544914
|
2018 |
|
|
IVACAFTOR
CHEMBL2010601
|
2012 |
Source Header